# Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection

> **NCT04560569** · PHASE2 · UNKNOWN · sponsor: **Frontier Biotechnologies Inc.** · enrollment: 20 (estimated)

## Conditions studied

- HIV/AIDS

## Interventions

- **DRUG:** Albuvirtide
- **DRUG:** 3BNC117 Antibody

## Key facts

- **NCT ID:** NCT04560569
- **Lead sponsor:** Frontier Biotechnologies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-30
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560569, "Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04560569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*